TBPH THERAVANCE BIOPHARMA INC revenue, earnings and financials

For the quarter ended June 30, 2026, THERAVANCE BIOPHARMA INC reported revenue of $20.7M (down 20.9% from a year earlier), net income of −$5.90M and diluted EPS of −$0.11; over the last four quarters revenue was $104M and net income $53.8M; for the fiscal year ended December 2025 revenue was $107M, up 66.9% on the year before.

TBPH annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $107M, gross profit n/a, operating income −$3.60M, net income $106M (margin 98.5%), EPS $2.06
• Fiscal year ended Dec 2024: revenue $64.4M, gross profit n/a, operating income −$46.9M, net income −$56.4M (margin -87.6%), EPS −$1.15
• Fiscal year ended Dec 2023: revenue $57.4M, gross profit n/a, operating income −$56.0M, net income −$55.2M (margin -96.1%), EPS −$1.00
• Fiscal year ended Dec 2022: revenue $51.3M, gross profit n/a, operating income −$92.0M, net income $872M (margin 1698.5%), EPS $11.85
• Fiscal year ended Dec 2021: revenue $55.3M, gross profit n/a, operating income −$258M, net income −$199M (margin -360.6%), EPS −$2.87

TBPH quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $20.7M (down 20.9% year over year), net income −$5.90M, EPS −$0.11
• Quarter ended Mar 31, 2026: revenue $17.7M (up 15.0% year over year), net income −$4.93M, EPS −$0.10
• Quarter ended Dec 31, 2025: revenue $45.9M (up 144.7% year over year), net income $61.0M, EPS $1.15
• Quarter ended Sep 30, 2025: revenue $20.0M (up 18.5% year over year), net income $3.62M, EPS $0.07
• Quarter ended Jun 30, 2025: revenue $26.2M (up 83.7% year over year), net income $54.8M, EPS $1.08
• Quarter ended Mar 31, 2025: revenue $15.4M (up 6.1% year over year), net income −$13.6M, EPS −$0.27
• Quarter ended Dec 31, 2024: revenue $18.8M (up 6.8% year over year), net income −$15.5M, EPS −$0.31
• Quarter ended Sep 30, 2024: revenue $16.9M (up 7.5% year over year), net income −$12.7M, EPS −$0.26
• Quarter ended Jun 30, 2024: revenue $14.3M (up 3.7% year over year), net income −$16.5M, EPS −$0.34
• Quarter ended Mar 31, 2024: revenue $14.5M (up 39.2% year over year), net income −$11.7M, EPS −$0.24
• Quarter ended Dec 31, 2023: revenue $17.6M (up 19.9% year over year), net income −$8.51M, EPS −$0.17
• Quarter ended Sep 30, 2023: revenue $15.7M (up 26.0% year over year), net income −$8.95M, EPS −$0.17
• Quarter ended Jun 30, 2023: revenue $13.7M (up 24.4% year over year), net income −$15.6M, EPS −$0.28
• Quarter ended Mar 31, 2023: revenue $10.4M (down 21.1% year over year), net income −$22.1M, EPS −$0.35
• Quarter ended Dec 31, 2022: revenue $14.6M (down 2.0% year over year), net income −$10.4M, EPS −$0.15
• Quarter ended Sep 30, 2022: revenue $12.5M (down 5.6% year over year), net income $917M, EPS $12.14
• Quarter ended Jun 30, 2022: revenue $11.1M (down 14.4% year over year), net income −$8.19M, EPS −$0.11
• Quarter ended Mar 31, 2022: revenue $13.2M (down 7.4% year over year), net income −$25.9M, EPS −$0.34
• Quarter ended Dec 31, 2021: revenue $14.9M, net income −$32.0M, EPS −$0.43
• Quarter ended Sep 30, 2021: revenue $13.2M, net income −$35.3M, EPS −$0.48

TBPH cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $239M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$11.5M, share buybacks $445K
• Fiscal year ended Dec 2023: operating cash flow −$27.0M, share buybacks $197M
• Fiscal year ended Dec 2022: operating cash flow −$187M, share buybacks $129M
• Fiscal year ended Dec 2021: operating cash flow −$208M, share buybacks n/a

TBPH balance sheet

• Jun 30, 2026: cash $220M, total assets $470M, total liabilities n/a, shareholders' equity $290M
• Mar 31, 2026: cash $288M, total assets $472M, total liabilities n/a, shareholders' equity $291M
• Dec 31, 2025: cash $168M, total assets $486M, total liabilities n/a, shareholders' equity $297M
• Sep 30, 2025: cash $175M, total assets $415M, total liabilities n/a, shareholders' equity $233M
• Jun 30, 2025: cash $282M, total assets $426M, total liabilities n/a, shareholders' equity $225M
• Mar 31, 2025: cash $111M, total assets $344M, total liabilities n/a, shareholders' equity $166M
• Dec 31, 2024: cash $37.8M, total assets $354M, total liabilities n/a, shareholders' equity $176M
• Sep 30, 2024: cash $23.4M, total assets $356M, total liabilities n/a, shareholders' equity $186M

What is TBPH's revenue?

THERAVANCE BIOPHARMA INC reported $104M of revenue over its last four quarters, through June 30, 2026.

Is TBPH profitable?

Yes. THERAVANCE BIOPHARMA INC earned $53.8M over the last four quarters.

What is TBPH's EPS?

Diluted earnings per share over the last four quarters were $1.01; −$0.11 in the latest quarter.

TBPH ownership and insider trades · All stocks